New Research Reveals Expanded Profile of Eating Disorders Beyond Underweight Individuals

New study uncovers that ARFID affects adults with higher body weight, highlighting the need for revised diagnosis and tailored treatment approaches. Learn more about the expanding understanding of eating disorders.
Recent research conducted by Leipzig University Medical Center has expanded our understanding of eating disorders, particularly ARFID (avoidant/restrictive food intake disorder). Traditionally associated with children or underweight individuals, ARFID is now recognized to affect adults across a broader weight spectrum, including those with higher body weight. The study, recently published in the journal Psychotherapy and Psychosomatics, involved 369 adults who completed online surveys and some underwent clinical interviews. Findings revealed that 34% of adults with ARFID had elevated body weight. Many of these individuals exhibit selective eating behaviors, experience significant psychosocial impairment, and have increased risks of metabolic health issues. Notably, higher-weight participants often express concerns about their body image and weight, yet in clinical settings, these concerns are frequently misinterpreted, leading to underdiagnosis. Experts highlight that current diagnostic tools and screening procedures need to be revised to encompass this population, emphasizing the importance of tailored treatment strategies. This research is critical in closing diagnostic gaps and improving care for all individuals affected by ARFID. Follow-up studies are ongoing to further explore causes and optimal treatments for the disorder.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Addressing the Gap in Oncology Education: Preparing Doctors for Cannabis-Related Patient Inquiries
Many oncology trainees feel unprepared to advise cancer patients on medical cannabis due to limited education and evidence. Experts emphasize the need for structured training to improve patient care and shared decision-making.
FDA Approves Twice-Yearly Injectable HIV Prevention: What You Need to Know About Lenacapavir
The FDA has approved lenacapavir, a long-acting injectable drug for HIV prevention, administered twice a year, offering a new effective and discreet option for at-risk populations worldwide.